Treatment of hepatocellular carcinoma with transcatheter arterial embolization. Analysis of prognostic factors
β Scribed by Kenji Taniguchi; Keisuke Nakata; Yuji Kato; Yoshiaki Sato; Keisuke Hamasaki; Shohtaro Tsuruta; Shigenobu Nagataki
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 482 KB
- Volume
- 73
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Background. Modulation of serum levels of circulating cytokines and inflammatory responses with a serine protease inhibitor was studied in 34 patients with hepatocellular carcinoma (HCC) after transcatheter arterial embolization (TAE). Methods. The 34 patients were randomly divided into two groups:
## BACKGROUND. Transcatheter arterial chemoembolization (TACE) has been used as a palliative treatment for patients with unresectable hepatocellular carcinoma (HCC), but its prognostic usefulness has not previously been clarified. ## METHODS. The authors reviewed all patients treated at their ins
The current study was conducted to evaluate retrospectively the effects of three kinds of regimens used in transcatheter arterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC) and patients' prognosis, and to analyze their prognostic factors. ## METHODS. The
## Background: The long term efficacy of combination therapy with transcatheter arterial embolization (tae) followed by percutaneous ethanol injection (pei) was studied in patients with large primary hepatocellular carcinoma (hcc) tumors and cirrhosis. ## Methods: The series included 83 patients